CompletedNCT05257265
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
Researchers compared Centanafadine Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Medication studyAges 13–17United States
Understand this study
What did researchers investigate?
Researchers compared Centanafadine Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 2, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 459
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT05257265
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Adolescents With Attention-deficit/Hyperactivity Disorder
Get this study by email
Recruitment & locations
CompletedNew York
Questions about this study
What did researchers investigate?
Researchers compared Centanafadine Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Centanafadine Hydrochloride.
Who was this study for?
This study was for people with ADHD. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
